Drug
Tapinarof clinical trials
Also written DMVT-505 and WBI-1001.
- studies test it
- 34
- open now
- 5
- in phase 3
- 12
- first study started
- 2008
Keep track of what changes. Save the tapinarof studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Brand
Development codes
Other names
Studies by the year they started
34 studies that test it; most in 2021 (6)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2013 | 1 |
| 2015 | 4 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 4 |
| 2021 | 6 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 3 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 6
- Phase 2
- 10
- Phase 3
- 12
- Phase 4
- 6
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 24 · Other 10
Organon and Co (12) · GlaxoSmithKline (6) · Welichem Biotech Inc. (3) · Peking University People's Hospital (3) · Indiana University (1) · Sun Pharmaceutical Industries, Inc. (1) · Teva Pharmaceuticals USA (1) · Psoriasis Treatment Center of Central New Jersey (1)
Often tested with
Tested in the same studies.
Betamethasone dipropionate (1) · Betamethasone (1) · Triamcinolone (1) · Fluorouracil (1) · Calcipotriene (1) · Crisaborole (1) · Tacrolimus (1) · Adalimumab (1)
Studies
Open first, then newest update. How each study uses tapinarof is read from its arms, and is right about nine times in ten.
Testing it · 34
- Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant)Enrolling by invitationPhase 2/3Wake Forest University Health SciencesNCT05981118Written as Tapinarof
- Efficacy and Safety of Benvitimod Cream in Cutaneous T-Cell LymphomaNot yet recruitingPhase 2Peking University First HospitalNCT07658924Written as Benvitimod Cream
- Efficacy of Topical Tapinarof Versus Betamethasone in the Treatment of Plaque PsoriasisNot yet recruitingPhase 4Pakistan Institute of Medical SciencesNCT07635043Written as Tapinarof Cream 1%
- Utilization of a Microdevice for Psoriasis and Atopic DermatitisNot yet recruitingPhase 4University of California, San FranciscoNCT07352566Written as Tapinarof
- Tapinarof for Cutaneous Lupus ErythematosusEnrolling by invitationEarly Phase 1Northwestern UniversityNCT06661213Written as Tapinarof
- A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic DermatitisSuspendedPhase 3Organon and CoNCT07265479Written as Tapinarof cream, 1%
- Study to Evaluate the Safety and Efficacy of Tapinarof in Adults With Palmoplantar KeratodermaActive, not recruitingPhase 2Indiana UniversityNCT06561321Written as Tapinarof
- A Study Comparing Tapinarof Cream 1% and Vtama® Cream 1% in the Treatment of Plaque Psoriasis.CompletedPhase 1Sun Pharmaceutical Industries, Inc.NCT07546214Written as Tapinarof Cream, 1%
- Tapinarof for the Treatment of Plaque Psoriasis in Pediatric SubjectsActive, not recruitingPhase 3Organon and CoNCT05172726Written as tapinarof cream, 1%
- Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque PsoriasisCompletedPhase 3Teva Pharmaceuticals USANCT06742957Written as Tapinarof Cream 1%
- Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic DermatitisCompletedPhase 2Organon and CoNCT05186805Written as Tapinarof cream, 1%
- Tapinarof for the Treatment of Atopic Dermatitis in Children and AdultsCompletedPhase 3Organon and CoNCT05014568Written as tapinarof cream, 1%
- Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102)CompletedPhase 3Organon and CoNCT05032859Written as tapinarof cream, 1%
- Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic DermatitisCompletedPhase 3Organon and CoNCT05142774Written as Tapinarof cream, 1%
- Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)CompletedPhase 3Organon and CoNCT04053387Written as tapinarof cream, 1%
- Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque PsoriasisCompletedPhase 2Organon and CoNCT04042103Written as Tapinarof cream, 1%
- Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002)CompletedPhase 3Organon and CoNCT03983980Written as Tapinarof
- A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck RegionCompletedPhase 4Organon and CoNCT05789576Written as VTAMA (tapinarof) cream, 1%
- A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque PsoriasisCompletedPhase 4Organon and CoNCT05680740Written as VTAMA® (tapinarof) Cream 1%
- Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001)CompletedPhase 3Organon and CoNCT03956355Written as Tapinarof
Codes
What other systems call tapinarof · ClinicalTrials.gg INT006049
- MeSH (NLM) C571829tapinarofConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 84HW7D0V04TAPINAROFConfirmed FDA, NLM, Wikidata
- RxNorm 2602286One source FDA
- Wikidata Q76386711tapinarofConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152511TapinarofOne source FDA
- DrugBank DB06083One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C571829 | tapinarof | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 84HW7D0V04 | TAPINAROF | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2602286 | — | One source FDA |
| Wikidata | Q76386711 | tapinarof | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152511 | Tapinarof | One source FDA |
| DrugBank | DB06083 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.